2seventy bio Inc. (TSVT) News
Filter TSVT News Items
TSVT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TSVT News From Around the Web
Below are the latest news stories about 2SEVENTY BIO INC that investors may wish to consider to help them evaluate TSVT as an investment opportunity.
US Penny Stocks To Watch In December 2024As U.S. markets experience a mixed performance with the S&P 500 and Nasdaq Composite recently hitting record highs but facing resistance, investors are keenly watching for opportunities that might offer substantial returns. Though the term 'penny stock' might sound like a relic of past trading days, the opportunity it points to is still relevant. For those looking to invest in smaller or newer companies, penny stocks can offer surprising value when built on solid financial foundations,... |
US$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest ResultsShareholders in 2seventy bio, Inc. ( NASDAQ:TSVT ) had a terrible week, as shares crashed 22% to US$3.92 in the week... |
2seventy bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag2seventy bio ( NASDAQ:TSVT ) Third Quarter 2024 Results Key Financial Results Revenue: US$13.5m (up 13% from 3Q 2023... |
2seventy bio Reports Third Quarter Financial Results and Recent Operational ProgressCAMBRIDGE, Mass., November 12, 2024--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the third quarter ended September 30, 2024. |
3 Promising US Penny Stocks With At Least $100M Market CapAs U.S. stock markets reach record highs following the recent presidential election, investors are keenly exploring diverse opportunities across various sectors. Penny stocks, though often overlooked, represent a niche where smaller or newer companies can offer significant growth potential at lower price points. While the term may seem outdated, these stocks can still be compelling investments when backed by strong financial health and solid fundamentals. |
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor ConferenceCAMBRIDGE, Mass., November 04, 2024--2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. |
High Growth Tech Stocks To Watch In October 2024Over the last 7 days, the United States market has dropped by 1.0%, yet it has seen a substantial rise of 38% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to capitalize on these promising earnings projections. |
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue PerformanceCAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant. |
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare ConferenceCAMBRIDGE, Mass., August 29, 2024--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024 at 12:20 p.m. ET in New York. |
2seventy bio, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearLast week saw the newest quarterly earnings release from 2seventy bio, Inc. ( NASDAQ:TSVT ), an important milestone in... |